Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
On the heels of his study, Dr. James Berenson —– an oncologist specializing in multiple…
read more
IMBCR & Emory University’s Big Discovery!!!
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…
read more
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…
read moreDedication of “Determination”
The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication…
read moreUnderstanding Myeloma News About Secondary Cancers and Clotting
Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid)…
read moreOncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of…
read moreThe histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg…
read moreKyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
The results of this landmark study should be welcomed news to cancer patients across the…
read moreCounterpoints: To Transplant or Not To Transplant
More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is…
read moreMultiple Myeloma: ‘Old Rules’ No Longer Apply
Original Article Writen by: Robert Carlson – Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple…
read more